Moderna

Traded on the St. Petersburg Stock Exchange
Moderna is an American biotechnology company based in Massachusetts. Founded in 2010. The priority line of activity is the development of medical products based on messenger RNA. He is one of the first developers of the COVID-19 vaccine.
Moderna stock price chart
-28%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Moderna balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Moderna cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Moderna multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Moderna profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Moderna assets
Moderna cash flows

Moderna shares

TickerNameTypeNominal valueISINPrice
MRNA:USModerna, Inc.Common share-US60770K1079$105.4
MRNA-RM:RMModernaCommon share$0.0001US60770K1079RUB 10,160
Moderna news
02.11.2023
Moderna's GAAP loss for 9 months of 2023 was $4.931 billion, against a profit of $6.897 billion in the prior year. Revenue decreased 3.5 times to $4.037 bln vs. $14.179 bln a year earlier.
03.08.2023
Moderna's GAAP loss for 6 months of 2023 was $1.301 billion, against a profit of $5.854 billion in the prior year. Revenue declined 5-fold to $2.206 billion versus $10.815 billion a year earlier.
04.05.2023
Moderna's GAAP net income for 3 months of 2023 was $0.079 billion, down many times from $3.657 billion in the previous year. Revenue decreased 3.3 times to $1.862 billion from $6.066 billion a year earlier.
23.02.2023
Moderna's GAAP net income for 2022 was $8.362 billion, down 31.5% from $12.202 billion the previous year. Revenue increased 4.3% to $19.263 billion from $18.471 billion a year earlier.
General information
Company nameModerna
Tags#biotechnology, #s&p500 index, #vaccines
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 6177146500
Mailing address200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Websitewww.modernatx.com
Information disclosurewww.sec.gov